We recently compiled a list of the Jim Cramer Shed Light on These 9 Stocks. In this article, we are going to take a look at ...
Vertex Pharmaceuticals (VRTX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Terence ...
Since two groundbreaking treatments were approved in late 2023, only a handful of patients have been able to access the ...
Vertex Pharmaceuticals' newly FDA-approved non-opioid analgesic, Journavx, offers a groundbreaking alternative for managing ...
U.S. officials have approved a new type of pain drug designed to eliminate the risks of addiction and overdose associated ...
Barclays analyst Gena Wang raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $435 from $418 and keeps an Equal Weight rating ...
Nondividend payers, such as the fund's positions in Vertex Pharmaceuticals and Royal Caribbean Group, are capped at 5%. While the strategy has excluded alcohol or tobacco companies previously ...
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF ...